Leniolisib for Immune Dysregulation in PIDs

NCT06549114 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunodeficiency Disorders (PIDs)

Interventions

DRUG: Leniolisib

Sponsor

Pharming Technologies B.V.